Cited 193 time in
Molecular and Chemical Regulation of the Keap1-Nrf2 Signaling Pathway
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Keum, Young-Sam | - |
| dc.contributor.author | Choi, Bu Young | - |
| dc.date.accessioned | 2024-08-08T01:31:14Z | - |
| dc.date.available | 2024-08-08T01:31:14Z | - |
| dc.date.issued | 2014-07 | - |
| dc.identifier.issn | 1420-3049 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/15253 | - |
| dc.description.abstract | Extracellular and intracellular oxidants or electrophiles are key contributors to the damages in cellular macromolecules, such as DNA, proteins and lipids. Nrf2 is a master transcription factor that modulates a cellular antioxidant response program and plays an important role in the protection against oxidants and electrophiles. Keap1 is a regulator of Nrf2 by serving as a substrate adaptor for Cullin3-dependent E3 ubiquitin ligase. While Nrf2 activation is a feasible strategy for treatment of age-related diseases, aberrant Nrf2 activation also confers a selective growth advantage of tumor cells during chemotherapy or radiotherapy. In the present review, we provide an overview of the Keap1-Nrf2-ARE system, the domain organization of Nrf2 and Keap1, and the regulatory mechanisms of Nrf2 proteolysis by Keap1. We also discuss how Nrf2 prevents tumor promotion, hampers the sensitivity of selected tumors against chemotherapy or radiotherapy, and reprograms the metabolism to facilitate the tumor proliferation. Finally, we illustrate the current status in the development of Nrf2 chemical activators and inhibitors for the use of potential chemopreventive agents and chemotherapeutic adjuvants, respectively. | - |
| dc.format.extent | 16 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | MDPI AG | - |
| dc.title | Molecular and Chemical Regulation of the Keap1-Nrf2 Signaling Pathway | - |
| dc.type | Article | - |
| dc.publisher.location | 스위스 | - |
| dc.identifier.doi | 10.3390/molecules190710074 | - |
| dc.identifier.scopusid | 2-s2.0-84904816048 | - |
| dc.identifier.wosid | 000340036200084 | - |
| dc.identifier.bibliographicCitation | MOLECULES, v.19, no.7, pp 10074 - 10089 | - |
| dc.citation.title | MOLECULES | - |
| dc.citation.volume | 19 | - |
| dc.citation.number | 7 | - |
| dc.citation.startPage | 10074 | - |
| dc.citation.endPage | 10089 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
| dc.subject.keywordPlus | TRANSCRIPTION FACTOR NRF2 | - |
| dc.subject.keywordPlus | FACTOR E2-RELATED FACTOR-2 | - |
| dc.subject.keywordPlus | CELL DEFENSE PATHWAY | - |
| dc.subject.keywordPlus | E3 UBIQUITIN LIGASES | - |
| dc.subject.keywordPlus | OXIDATIVE STRESS | - |
| dc.subject.keywordPlus | ANTIOXIDANT RESPONSE | - |
| dc.subject.keywordPlus | BEL-7402/ADM CELLS | - |
| dc.subject.keywordPlus | LUNG-CARCINOMA | - |
| dc.subject.keywordPlus | A549 CELLS | - |
| dc.subject.keywordPlus | CANCER | - |
| dc.subject.keywordAuthor | Keap1 | - |
| dc.subject.keywordAuthor | Nrf2 | - |
| dc.subject.keywordAuthor | ARE | - |
| dc.subject.keywordAuthor | oncogene | - |
| dc.subject.keywordAuthor | tumor suppressor gene | - |
| dc.subject.keywordAuthor | metabolism | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
